Metastatic lung cancer remains one of the the most challenging malignancies to treat, with limited therapeutic options and poor survival rates. Recent advances in gene-editing technologies, particularly CRISPR-Cas9, have opened new avenues for targeted cancer therapy. In vivo CRISPR-based interventions offer a promising strategy to directly modify cancer-related genes, inhibit tumor growth, and prevent metastasis. This article explores recent developments in in vivo CRISPR therapy for metastatic lung cancer using mouse models, highlighting key findings, challenges, and future directions.
CRISPR-Cas9 enables precise editing of genomic sequences, allowing researchers to disrupt oncogenes, restore tumor suppressor genes, or enhance immune responses against cancer cells. For metastatic lung cancer, in vivo delivery of CRISPR components directly to tumor sites or circulating tumor cells (CTCs) could provide a powerful therapeutic approach.
Several studies have demonstrated the potential of CRISPR-Cas9 in treating lung cancer metastasis in mouse models:
Mutations in KRAS and EGFR are common drivers of non-small cell lung cancer (NSCLC) and metastasis.
Researchers have used lipid nanoparticles (LNPs) or adeno-associated viruses (AAVs) to deliver CRISPR-Cas9 specifically to lung tumors, disrupting mutant KRAS or EGFR and significantly reducing tumor burden and metastatic spread (1).
The TME plays a crucial role in promoting metastasis. CRISPR has been used to knock out PD-L1 in cancer cells, enhancing T-cell-mediated tumor killing (2).
Another approach involves editing TGF-β or MMP9 to suppress extracellular matrix remodeling, inhibiting metastatic invasion (3).
CRISPR-edited CAR-T cells targeting lung cancer antigens (e.g., MUC1, mesothelin) have shown efficacy in reducing metastatic lesions (4).
Natural killer (NK) cells engineered with CRISPR to enhance cytotoxicity have also demonstrated anti-metastatic effects in preclinical models (5).
Knockout of CD44 or ALDH1 (genes involved in cancer stem cell maintenance) reduced metastatic potential in lung cancer models (6).
CRISPR interference (CRISPRi) has been used to silence SNAIL or TWIST, key regulators of epithelial-mesenchymal transition (EMT), blocking metastasis (7).
Despite promising results, several hurdles remain:
Off-target effects: Unintended genomic edits may lead to toxicities. Improved Cas9 variants (e.g., HiFi-Cas9) and single-base editors are being tested for higher precision.
Delivery efficiency: LNPs and AAVs show promise, but optimizing tissue specificity and avoiding immune clearance is critical.
Immune responses: Pre-existing antibodies against Cas9 or viral vectors may limit therapeutic efficacy.
Multiplexed editing: Simultaneously targeting multiple oncogenic pathways could enhance therapeutic efficacy.
Ex vivo CRISPR-edited cell therapies: Combining CRISPR with adoptive cell transfer (e.g., T cells, macrophages) may improve metastatic control.
Non-viral delivery systems: Advances in nanoparticle formulations (e.g., gold nanoparticles, exosomes) could improve CRISPR delivery.
In vivo CRISPR therapy holds immense potential for treating metastatic lung cancer, as demonstrated in mouse models. While challenges in delivery specificity and safety remain, ongoing innovations in gene-editing technology and nanomedicine are paving the way for clinical translation. Future studies should focus on optimizing CRISPR delivery systems and evaluating long-term therapeutic outcomes in advanced preclinical models.
